Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device

Core Insights - Aetna has authorized a claim for the PoNS Device at an out-of-network negotiated price of $18,350, joining Anthem and United in providing reimbursement for the device [1][2] - The company is actively pursuing broader in-network coverage for the PoNS Device at list price and aims to align commercial payments with the rates offered by the VA/DoD at $26,228 [2] - The PoNS Device is indicated for short-term treatment of gait deficits due to mild-to-moderate symptoms from multiple sclerosis (MS) and is used in conjunction with physical rehabilitation exercises [3][4] Company Overview - Helius Medical Technologies, Inc. is focused on delivering innovative neurotech solutions for neurologic deficits, with the Portable Neuromodulation Stimulator (PoNS) as its first commercial product [5] - The PoNS Device delivers neurostimulation through a mouthpiece and is primarily used at home to improve balance and gait in patients aged 22 and over [3][5] - The device has shown effectiveness in treating gait and balance issues, significantly reducing the risk of falls in stroke patients in Canada [4]